ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Mesothelioma is on this study

  • ClinicalTrials.gov filed the study under Mesothelioma; it no longer does.
  • GPT-6 Astra (Medium) judged the term right family, but the study is about something narrower. Oct 20 (day only)
4 links1 made here, not in the record6 judgments3 judges (the rules as one: Rule based)1 record change seen
GPT-6 Astra (Medium)Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT05425576OT-101 in Combination WithPembrolizumab in SubjectsWith Malignant PleuralMesothelioma Failing toRespond to CheckpointInhibitionOncotelic Inc.Phase 2 · not yet recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSMesothelioma, MalignantThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionMesotheliomaNo longer in the registry's filing›Oct 20 · GPT-6 Astra (Medium) · Finer: Mesothelioma, MalignantNov 19 · Rule based · The filing now says what the reading saidThe filing now says what the read…DRUGSTrabedersenEntry “OT-101”, read by our name rule›Nov 18 · Rule based · TestedTestedPembrolizumabMade here · Found by reading; no entr…›Nov 1 · Claude Opus 5.5 · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
Oct 20MesotheliomaGPT-6 Astra (Medium)Finer: Mesothelioma, MalignantCurrent
Nov 1Pembrolizumabmade hereClaude Opus 5.5BackgroundCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 14Mesothelioma, MalignantRule based · condition-kind ruleFinest filed termCurrent
Nov 18TrabedersenRule based · role ruleTestedCurrent
Nov 19MesotheliomaRule based · nightly checkThe filing now says what the reading saidCurrent
As of nowMesothelioma, MalignantRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.